Imohtep (Great Doctors Series): Architect, Priest, Healer, Genius
Dr. RR Baliga's 'Podkast for the Kurious Doc'
What does it take to be remembered for 3,000 years? 🏺 Meet Imhotep—chancellor, architect of the Step Pyramid, and later revered as a god of healing. From stone structures that defy time to ideas that shaped medicine and myth, his legacy is both historical and philosophical. As highlighted in early narratives, he was not just a builder of monuments—but a builder of meaning. A timeless reminder: true impact is not just what we create—but what endures. ✨ #GreatDoctors #HistoryOfMedicine #Innovation #AncientWisdom #Leadership
info_outline
Eat Smart. Live Long. ❤️🥗📘
Dr. RR Baliga's 'Podkast for the Kurious Doc'
❤️ New in Circulation: the 2026 AHA Dietary Guidance to Improve Cardiovascular Health distills prevention into 9 elegant features—maintain healthy weight, emphasize vegetables/fruits, choose whole grains, favor healthier proteins and unsaturated fats, minimize ultraprocessed foods, added sugars, and sodium, and avoid starting alcohol for health. Food, here, is not garnish; it is strategy. 🥗🌾🩺 #Cardiology #Prevention #Nutrition
info_outline
Environment. Epigenome. Early Colorectal Cancer. 🌍🧬🧫
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧬⚠️ Genes. Toxins. Tumors. A compelling Nature Medicine study uncovers how the exposome—our lifetime environmental exposures—leaves epigenetic fingerprints linked to early-onset colorectal cancer. 🚜 A striking signal: picloram exposure shows consistent association across cohorts and real-world US data. 📊 Reinforces known risks (smoking, diet, education) while revealing novel environmental drivers. 💡 The message is clear: cancer prevention may begin far upstream—in policy, environment, and early-life exposures. #ColorectalCancer #Exposome...
info_outline
Can AI think like a physician? 🧠🤖
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Can AI think like a physician? 🧠🤖 A landmark Science 2026 study shows LLMs outperform physicians in structured diagnostic reasoning across NEJM cases and real-world emergency scenarios. 📊 Accuracy gains were striking—especially in early triage where uncertainty is highest. Yet, the story is not replacement, but partnership. 🤝 The real challenge now: translating benchmark brilliance into safe, equitable, real-world care. ⚖️ AI is no longer a tool—it’s becoming a colleague. The question is: how do we train, trust, and integrate it? 🚀
info_outline
TB: Point-of-Care. Precision. Progress. 📍🧠📈
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A quiet revolution in tuberculosis diagnostics is here. 🧪🌍 This NEJM study shows that MiniDock MTB, a rapid swab-based molecular test, delivers Xpert-level accuracy with minimal training and no adverse events—all in a near–point-of-care format. ⏱️🧠 Key insights: 🔹 Sensitivity: 85.7% (sputum), 79.6% (tongue) 🔹 Specificity: >97–99% 🔹 Strong performance vs smear microscopy (+24% sensitivity) 🔹 Usability score: 75—ready for real-world deployment The implications are profound: 👉 Noninvasive testing for patients unable to produce sputum...
info_outline
Fueling Immunity: When Eating Becomes Therapy 🍽️💊🛡️
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A meal may be more than nutrition—it may be immunotherapy. 🍽️⚡ In a striking Nature study, T cells sampled just 6 hours after feeding showed enhanced metabolic fitness, cytokine production, and persistence compared to the fasted state. 🧠🔥 Mechanistically, chylomicron-derived lipids → LDLR → mTORC1 → protein translation, fueling durable immune function. Even more compelling: postprandial CAR-T cells demonstrated superior cytotoxicity. Clinical implication? Timing may matter—before vaccines, before cell therapy, before immune engagement. ⏱️ Feed. Fuel. Fight....
info_outline
CKD. Control BP. Cardioprotection. 🧬❤️📉
Dr. RR Baliga's 'Podkast for the Kurious Doc'
BP Lowering in CKD: Consistent. Comprehensive. Compelling. 📉🫀 A landmark individual-participant meta-analysis (285K+ patients) shows that every 5 mm Hg reduction in systolic BP reduces major cardiovascular events by ~10%—across all CKD stages. Key insight: the benefit holds even at lower BP levels and across drug classes. ⚖️ But in CKD + diabetes, the effect attenuates—reminding us that biology resists simplicity. 🧠 The message is clear: BP control remains one of the most powerful, scalable tools in CKD care. Precision is next. Implementation is everything. 🚀
info_outline
Great Doctors Series: Charaka-Balance. Body. Beginnings. 🌿🧠📜
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🌿 Balance. Body. Beginnings. Long before modern medicine spoke of personalization and prevention, Charaka articulated a remarkably sophisticated vision of health—rooted in balance, biology, and behavior. From the Charaka Samhita to the concept of doshas (vata, pitta, kapha), his work reflects an early systems-based approach that continues to echo in today’s precision and lifestyle medicine. This infographic from Dr RR Baliga’s Podkast for the Kurious Doc 🎙️🧠 explores how ancient insights still inform modern thinking ✨ Where curiosity meets clarity #Ayurveda #MedicalHistory...
info_outline
Persistant Atrial Fibrillation: Pulse Field Ablation Dominates
Dr. RR Baliga's 'Podkast for the Kurious Doc'
⚡🫀 Shock. Silence. Success — A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF. In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: 📊 Success: 56% vs 30% 📉 HR: 0.46 (P<0.001) 💓 Lower arrhythmia burden (−6.5%) Safety remained comparable, with primary events at 5.1%. A compelling case for early, energy-based rhythm control—precision over pharmacology. #Cardiology #Electrophysiology #AtrialFibrillation #NEJM #Innovation
info_outline
Cancer of the Heart: Pressure. Chromatin. Control. ❤️🔥🧬⚙️
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating Science (2026) study reveals why the heart is remarkably resistant to cancer. Mechanical load—through contraction and pressure—suppresses tumor proliferation via epigenetic remodeling. Unloading the heart doubled cancer cell proliferation, while load reduced histone methylation and chromatin compaction through Nesprin-2–mediated mechanotransduction. A striking paradigm: the beating heart is not just a pump—but a biomechanical tumor suppressor. 🫀⚙️🧬 @ICOSociety
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.